Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

NCT00956046 ·Status: COMPLETED ·Phase: PHASE2

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

NCT00943631 ·Status: COMPLETED ·Phase: PHASE2

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

NCT00954798 ·Status: COMPLETED ·Phase: PHASE2

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

NCT01023776 ·Status: COMPLETED ·Phase: PHASE4

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

NCT00979602 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

NCT01089660 ·Status: COMPLETED ·Phase: PHASE2

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

NCT00970177 ·Status: COMPLETED ·Phase: PHASE3

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

NCT01040078 ·Status: UNKNOWN ·Phase: PHASE3

Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects

NCT01422512 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects

NCT01357265 ·Status: COMPLETED ·Phase: PHASE2

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

NCT00133536 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

NCT00946179 ·Status: COMPLETED ·Phase: PHASE2

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

NCT00971906 ·Status: COMPLETED ·Phase: PHASE3

Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months

NCT00996307 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

H7N9 Boost in Healthy Adults

NCT02586792 ·Status: COMPLETED ·Phase: PHASE2

Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

NCT01928472 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)

NCT00973700 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults

NCT00943358 ·Status: COMPLETED ·Phase: PHASE1

Novartis H1N1 Vaccine in Pregnant Women

NCT00992719 ·Status: COMPLETED ·Phase: PHASE2

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

NCT00992212 ·Status: COMPLETED ·Phase: PHASE2

Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

NCT01023711 ·Status: COMPLETED ·Phase: NA

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

NCT00973349 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

NCT00951041 ·Status: COMPLETED ·Phase: PHASE2

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

NCT01855945 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)

NCT00989612 ·Status: COMPLETED ·Phase: PHASE2